The IPWG discusses the challenges and opportunities facing the pharmacogenomics industry

Abstract

Genomic data has been increasingly used by the pharmaceutical industry in the identification of therapeutic targets and the
development of precision medicine strategies. Large pharmaceutical corporations often acquire DNA samples from trial
participants and undertake pharmacogenomic (PGx) investigations as part of their standard operating procedure. However,
there are several obstacles to implementing PGx trials throughout clinical development. Among these obstacles include the
need to respond to a globally regulatory climate that is in a perpetual state of flux, difficulties in research design and clinical
execution, and rising worries about patient privacy. The availability of massive genetic databases connected to patient health
information, the rising usage of polygenic risk scores, and the direct sequencing of participants in clinical trials are all
examples of how advances in genomics are creating new possibilities for pharmaceutical firms. Companies in the
pharmaceutical industry that are involved in pharmacogenomics work together as part of the Industry Pharmacogenomics
Working Group (I-PWG). Here, the I-PWG offers a bird's-eye view of the initiatives being undertaken by the
pharmaceutical industry to meet these difficulties and seize new scientific openings.